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Brief exposure of rats to high-dose estrogen during the neonatal period interrupts prostate development in a lobe-specific manner and
predisposes the gland to dysplasia with aging, a phenomenon referred to as developmental estrogenization. Our previous studies have
revealed that these effects are initiated through altered steroid receptor expression; however, the immediate downstream targets remain
unclear. We have recently shown that developmental expression of Shh-ptc-gli is downregulated in the dorsolateral prostate following
estrogenization, and this is responsible, in part, for branching deficits observed in that prostatic region specifically. In the present study, we
examine the role of Fgf10 signaling during rat prostate development and as a mediator of the developmental estrogenized phenotype. Fgf10
and FgfR2iiib localize to the distal signaling center of elongating and branching ducts in separate prostate lobes where they regulate the
expression of multiple morphoregulatory genes including Shh, ptc, Bmp7, Bmp4, Hoxb13, and Nkx3.1. Ventral and lateral lobe organ
cultures and mesenchyme-free ductal cultures demonstrate a direct role for Fgf10/FgfR2iiib in ductal elongation, branching, epithelial
proliferation, and differentiation. Based on these findings, a model is proposed depicting the localized expression and feedback loops
between several morphoregulatory factors in the developing prostate that contribute to tightly regulated branching morphogenesis. Similar to
Shh-ptc-gli, neonatal estrogen exposure downregulates Fgf10, FgfR2iiib, and Bmp7 expression in the dorsolateral prostate while ventral lobe
expression of these genes is unaffected. Lateral prostate organ culture experiments demonstrate that growth and branching inhibition as well
as Fgf10/FgfR2iiib suppression are mediated directly at the prostatic level. Furthermore, exogenous Fgf10 fully rescues the growth and
branching deficits due to estrogen exposure. Together, these studies demonstrate that alterations in Fgf10 signaling are a proximate cause of
Shh-ptc-gli and Bmp7 downregulation that together result in branching inhibition of the dorsolateral prostate following neonatal estrogen
exposure.
D 2004 Elsevier Inc. All rights reserved.
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Development of the rat prostate gland is initiated late in
fetal life ( f18.5) when epithelial buds from the urogenital
sinus (UGS) penetrate into the surrounding urogenital
mesenchyme in ventral, lateral, and dorsal directions giving
rise to the separate ventral (VP), lateral (LP) and dorsal
lobes (DP), respectively. At the time of birth, the rat prostate0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.11.020
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E-mail address: gprins@uic.edu (G.S. Prins).is rudimentary, consisting of several solid, unbranched
epithelial cords, and branching morphogenesis followed
by cytologic and functional differentiation occurs during the
immediate postnatal period (Hayashi et al., 1991). While
androgens are both necessary and sufficient for prostate
morphogenesis, the direct targets of androgen action during
this developmental process are not well understood. In
addition to androgens, it is recognized that other hormones
influence prostate development including prolactin (Robert-
son et al., 2003), growth hormone (Ruan et al., 1999),
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alterations in the balance of these hormones lead to
distinctive changes in prostate development and function.
Work from our laboratory has shown that brief exposure of
the rat to estrogens during the critical neonatal period alters
prostate branching morphogenesis and cellular differentia-
tion in a dose-dependent manner (Prins and Birch, 1995;
Putz et al., 2001). If estrogenic exposures are high, these
disturbances lead to permanent and lobe-specific imprints of
the prostate, a process referred to as developmental estro-
genization. While all lobes present with hypoplasia,
epithelial differentiation defects and altered secretory
function are most pronounced in the VP whereas the DP
and LP exhibit marked branching deficits (Chang et al.,
1999; Habermann et al., 2001; Prins, 1992; Prins et al.,
1993; Pu et al., 2004). Importantly, developmental estro-
genization is associated with severe prostatic lesions with
aging including epithelial hyperplasia, prostatic intraepithe-
lial neoplasia (PIN), adenomas, and chronic inflammation
(Gilleran et al., 2003; Prins, 1997; Putz and Prins, 2002).
Thus, neonatal estrogenization of the rat prostate serves as a
useful model for evaluating the role of endogenous and
exogenous estrogens as a predisposing factor for prostatic
disease later in life.
A fundamental understanding of the estrogenization
phenomenon requires knowledge of the immediate cellular
and molecular changes induced by estrogens that, in turn,
alter the course of prostatic development long after hormone
withdrawal. Toward that end, our studies have revealed that
high-dose estrogens markedly alter the expression of key
steroid receptors within the developing prostate (for review,
see Prins et al., 2001b). Androgen receptors (ARs) are
permanently downregulated (Prins, 1992; Prins and Birch,
1995; Woodham et al., 2003) while estrogen receptor a
(ERa), progesterone receptor (PR), and retinoid receptors
RAR/RXR are upregulated in a cell-specific and lobe-
specific manner (Prins and Birch, 1997; Prins et al.,
2001a,b, 2002; Pu et al., 2003; Sabharwal et al., 2000).
The net result of these alterations is that prostate develop-
ment is no longer under predominant androgen regulation
but is rather driven by alternate steroids, principally estro-
gens and retinoids via their cognate receptors. We hypothe-
sized that the overall effect of these changes is the
programming, and organizational signals that normally
dictate prostate development during discrete temporal
windows are permanently and irretrievably altered.
Several genes that determine and regulate prostate
development include common and tissue-specific transcrip-
tion factors (e.g., Nkx3.1, FoxA1, Hoxa13, Hoxb13, and
Hoxd13) and secreted morphogens that establish reciprocal
cross-talk between stromal and epithelial cells via their
cognate receptors (e.g., Shh, Fgf7, Fgf10, Bmp7, Bmp4,
Tgfh, and activins) (for review, see Huang et al., 2004). In
the prostate, expression of these transcription and growth
factors varies along the length of the elongating ducts giving
rise to a unique distal signaling center that directs ductaloutgrowth and branching (Pu et al., 2004). Our recent
studies on Shh-ptc-gli expression in the developing rat
prostate revealed distal tip localization of this signaling
pathway with evidence for its direct involvement in
branching morphogenesis (Pu et al., 2004). Importantly,
Shh was shown to downregulate Fgf10 and upregulate
Bmp4 expression in the developing prostate, suggesting that
its effects on ductal branching may involve cross-talk with
growth factor networks. In the estrogenized prostate, Shh-
ptc-gli expression was rapidly downregulated in the LP and
DP but not in the VP that directly correlated with branching
inhibition in the DLP specifically. However, since prostatic
estrogenization is mediated through mesenchymal ERa
(Prins et al., 2001a,b), epithelial Shh downregulation is
likely mediated through mesenchymal paracrine factors. In
this study, we test the hypothesis that Fgf10 signaling may
be directly altered by neonatal estrogen exposure and that its
downstream actions may mediate specific aspects of the
estrogenized phenotype.
Fgf10 is expressed by mesenchymal cells and has been
previously identified as a critical morphogen involved in
branching morphogenesis of a number of organs including
the prostate gland (Bellusci et al., 1997; Cardoso, 2001;
Donjacour et al., 2003; Hoffman et al., 2002; Thomson and
Cunha, 1999; Weaver et al., 2000). Fgf10 is a member of
the fibroblast growth factor (Fgf) family of secreted
morphogens that consist of 23 known members (Ornitz
and Itoh, 2001; Raman et al., 2003). Fgfs have a high
affinity for heparin and glycosaminoglycans (GAGs), which
position them for interaction with membrane-associated
tyrosine kinase Fgf receptors (FgfR) on target cells
(Uematsu et al., 2000). The splice variant of FgfR2,
FgfR2iiib, is the specific receptor for Fgf10 and is
expressed by epithelial cells, thus establishing a stromal–
epithelial loop (Finch et al., 1995). In the prostate gland, as
in the lungs and other branched structures, Fgf10 expression
is spatially restricted to the distal aspects of the glands
where it is believed to function as a chemoattractant for
elongating ducts and an inducer of ductal branching through
stimulation of epithelial cell proliferation (Donjacour et al.,
2003; Lu et al., 1999; Thomson and Cunha, 1999). In other
systems, Fgf10 actions are also mediated, in part, through
regulation of multiple signaling cascades, including Shh
(Cardoso, 2001; Chuang and McMahon, 2003; Haraguchi et
al., 2000; Revest et al., 2001). Downstream gene targets of
Fgf10 action in the prostate gland have not been identified.
Regulation of Fgf10 signaling in developing organs is not
well understood at present. It is currently hypothesized that
localized regulation of Fgf10 expression at discreet foci may
be involved in tightly controlling branching at precise sites
(Chuang andMcMahon, 2003; Weaver et al., 2000). We have
recently shown that Shh downregulates Fgf10 expression in
the prostate gland (Pu et al., 2004) and proposed that focal
expression domains of Shh and Fgf10 play a role in
dichotomous branching (Pu et al., 2004). Tgfh1 has recently
been shown to downregulate prostatic Fgf10 expression
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mesenchymal Tgfh1 plays an important role during prostate
development and neonatal estrogens alter its levels and
localization (Chang et al., 1999). The issue of whether
androgens play a major role in regulating Fgf10 expression in
the prostate gland is presently unresolved. While dihydro-
testosterone markedly induced Fgf10 expression in cultured
prostate stromal cells (Lu et al., 1999), stimulation of Fgf10
expression by testosterone in rat VP organ culture was
modest, suggesting that androgens may not be a principal
Fgf10 regulator in vivo (Thomson and Cunha, 1999).
Nonetheless, it is possible that a shift from normal andro-
gen-dominated morphogenesis to developmental regulation
by alternate steroids including retinoids, as occurs after
neonatal estrogen exposure, may result in altered regulation
of Fgf10 expression. It is noteworthy that retinoic acid
selectively regulates Fgf10 expression in the gut (Desai et al.,
2004) and that loss of Fgf10 inhibition by retinoic acid in the
lungs is required for distal lung formation (Cardoso, 2001).
Finally, while FgfR2iiib is known to be expressed in prostatic
epithelial cells, its spatiotemporal expression pattern and its
regulation by steroids have not been previously examined.
The present study was designed to fully characterize the
staged, spatiotemporal expression of Fgf10 and FgfR2iiib in
separate developing rat prostate lobes and to further define
the role of this morphoregulatory pathway in prostate
growth, ductal branching, and epithelial differentiation. To
elucidate the mechanisms of these effects, we examined a
number of candidate genes as potential downstream targets
for Fgf10 action in the prostate gland. We then sought to
determine whether Fgf10 and FgfR2iiib expression are
regulated by estrogens in the developing prostate gland and
whether a disturbance in this signaling pathway may
directly mediate neonatal estrogenization. Our findings
demonstrate that Fgf10 and FgfR2iiib are localized to the
distal signaling center of elongating and branching prostatic
ducts and that this signaling pathway regulates several
developmental genes including Shh, Bmp4, Bmp7, Nkx3.1,
and Hoxb13. Neonatal estrogens directly suppress Fgf10
and FgfR2iiib expression both in vivo and in vitro in the LP
and DP but not the VP. Furthermore, organ culture studies
show that Fgf10 replacement can rescue LP growth and
branching inhibition as a result of estradiol administration.
Taken together, these findings support the hypothesis that
Fgf10 signaling plays a critical role, both directly and
indirectly through alterations in other morphoregulatory
genes, in mediating the estrogenized phenotype in the
dorsolateral prostate.Materials and methods
Animals
All rats were handled in accordance with the principles
and procedures of the Guiding Principles for the Care andUse of Animal Research and the experiments were approved
by the Institutional Animal Care Committee. Timed
pregnant female Sprague–Dawley rats were purchased from
Zivic-Miller (Pittsburgh, PA), housed individually in a
temperature (218C)- and light (14 h light/10 h dark)-
controlled room, and fed standard Purina rat chow
(Ralston-Purina, St. Louis, MO) ad libitum. The day of
birth was designated as day 0. All males from a single
mother were assigned to one of two groups and treated on
postnatal days (pnd) 0, 3, and 5 with subcutaneous
injections of either 25 Ag 17h-estradiol-3-benzoate
(Sigma-Aldrich Chemical Co., St. Louis, MO) in 25 Al of
peanut oil (Arachis sp.) or with oil alone as controls. Pups
were sacrificed by decapitation on pnd 1, 3, 6, 10, 15, 30, or
90 and the UGS–prostate complexes were dissected for
subsequent analysis. Thus pups killed on pnd 1 and 3 were
exposed to a single dose of estradiol on day 0 while
offsprings killed on pnd 6 and later were exposed three
times to estradiol.
In vitro estrogenic exposure
Since the in vivo estrogenic effects on Fgf10 and
FgfR2iiib expression were concentrated in the LP, in vitro
experiments were performed with this lobe to determine if the
effect was mediated directly at the prostatic level. LPs were
isolated from pups (n = 10) on pnd 0 and cultured for 6 days
as previously described (Pu et al., 2004) in basal organ culture
medium (BOCM) in the absence or presence of 20 AM
estradiol (Sigma-Aldrich) with medium changed every 48 h.
To limit experimental variability, contralateral lobes from a
single animal were paired and cultured with or without
estradiol. BOCM consisted of DMEM/F-12 (Invitrogen,
Carlsbad, CA), 108 M testosterone (Sigma-Aldrich), 50
Ag/ml gentamycin, and 1 insulin-transferrin-selenium
(Invitrogen). To monitor growth, daily photographs were
captured with a Burle video camera and Snappy ver. 3.0
software and 2D area was calculated using Zeiss Image ver.
3.0 software (Carl Zeiss, Inc., Thornwood, NY). After 6 days,
the urethral compartment was removed and the prostatic
compartment was used for RNA isolation and real-time RT-
PCR. In a separate series, the entire UGS–prostatic complex
(n = 6) was removed on pnd 0, cultured as above with and
without estradiol for 48 h, and fixed for subsequent whole
mount in situ hybridization.
To determine if the estrogenic effect could be reversed
with exogenous Fgf10, LPs were isolated from pups (n =
12) on pnd 0 and cultured as described above in (1)
BOCM + 0.5 Ag/ml BSA, (2) BOCM + BSA + 20 AM
estradiol, or (3) BOCM + estradiol + 0.5 Ag/ml Fgf10 (R&D
Systems, Minneapolis, MN). Heparin (2.5 Ag/ml; Sigma-
Aldrich) was added to each culture group for the first 48 h
of culture to aid in Fgf10 association with the extracellular
matrix (ECM). To allow direct comparisons, groups 2 and 3
used the two LPs from a single animal. Daily photographs
were taken to monitor growth and determine 2D area. On
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for subsequent immunocytochemistry.
Prostate organ culture and mesenchyme-free ductal culture
with Fgf10
To examine the effects of Fgf10 on normal prostate
development, rudimentary VPs and LPs (n = 6) were
removed on pnd 0 and paired lobes from a single pup were
cultured for 6 days in the presence or absence of 0.5 Ag/ml
Fgf10 in BOCM with 2.5 Ag/ml heparin for the first 48 h of
culture. Daily photographs were taken everyday to monitor
growth. On day 6, tissues were fixed and embedded in
paraffin for subsequent immunocytochemistry. In a separate
set of similarly treated LPs (n = 7), the cultures were pulsed
on day 6 with 10 AM BrdU (Sigma-Aldrich) for 2.5 h,
washed in PBS for 30 min, fixed overnight in methacarn,
and embedded in paraffin. To determine whether testoster-
one affects Fgf10 and FgfR2iiib expression, an additional
set (n = 8) of LPs and VPs was removed on pnd 0 and
contralateral lobes were cultured for 20 h in BOCM with or
without 108 M testosterone. The individual lobes were
homogenized and total RNA isolated for real-time RT-PCR
to quantitate Fgf10 and FgfR2iiib mRNA levels.
To examine the effects of Fgf10 on gene expression in
the normal developing prostate, rudimentary VPs (n = 8)
were removed on pnd 0 and paired lobes from a single pup
were cultured with or without exogenous Fgf10 in BOCM
minus testosterone. After 24 h, tissues were homogenized
and total RNA isolated for subsequent real-time RT-PCR. In
a separate series, the entire UGS–prostatic complex (n = 3)
was removed on pnd 0, cultured as above for 24 h, and fixed
for subsequent whole mount in situ hybridization.
Mesenchyme-free prostatic ductal cultures were per-
formed to examine the role of Fgf10 in ductal growth and
branching. VPs were removed on pnd 0 and digested with
0.05% collagenase (Sigma-Aldrich) in phenol-free Hank’s
salt solution (Sigma-Aldrich) containing 1% fetal bovine
serum (FBS; Sigma-Aldrich) for 45 min at 378C, washed
twice in Hank’s with 10% FBS, and the epithelium and
mesenchyme were separated with tungsten needles. The
epithelial ducts were further digested with 1.6 U/ml dispase
(BD Biosciences, San Jose, CA) for 10 min at 378C and
washed twice in Hank’s with 10% FBS. The distal epithelial
rudiments were embedded in growth factor reduced
Matrigel (BD Biosciences) and cultured for 44 h in culture
medium with 108 M testosterone or 0.5 Ag/ml Fgf10. To
examine the Fgf10 signaling pathway, Fgf10-treated ducts
were cultured in the presence of the Mek inhibitor U0126
(20 AM; Calbiochem, San Diego, CA). Mesenchyme-free
experiments were repeated 4–8 times.
Whole mount in situ hybridization (wmISH)
The UGS–prostatic complexes were fixed in 4% paraf-
ormaldehyde, dehydrated, and digested with proteinase K.Following prehybridization, tissues were hybridized over-
night at 608C with 0.5–0.6 Ag/ml digoxigenin-labeled RNA
probe, washed at high and low stringency, incubated
overnight at 48C in anti-digoxygenin alkaline phosphatase-
conjugated antiserum (Roche, Indianapolis, IN), and color
reacted with NBT and BCIP (Roche). To allow for temporal
and treatment comparisons, pnd 1, 3, and 6 prostatic
complexes from in vivo control and estrogenized rats were
processed together and direct comparisons were made
within each run. A minimum of four separate wmISH
assays were performed for Fgf10 and FgfR2iiib from in
vivo experiments. The prostates were photographed with a
Carl Zeiss AxioCam color digital camera using AxioVision
ver. 2.0.5 software. To identify cellular localization of gene
expression, wmISH-stained tissues were cross-sectioned at
10 Am.
The rat Fgf10, FgfR2iiib, and Bmp7 templates were
prepared by TA cloning 498-, 570-, and 344-bp PCR
fragments, respectively, into PCR II vectors. The plasmids
were sequenced to confirm PCR precision and orientation.
The plasmids were linearized with the following restriction
enzymes: Fgf10 with EcoRV (antisense) and SpeI (sense),
FgfR2iiib with HindIII (antisense) and XhoI (sense), and
Bmp7 with SpeI (antisense) and NotI (sense). Digoxigenin-
labeled RNA probes were prepared by in vitro transcription
using appropriate RNA polymerases (DIG RNA labeling
kit, Roche).
Immunocytochemistry (ICC)
Fgf10, FgfR2iiib, and p63, a basal cell marker, were
localized by immunocytochemistry as described (Prins et al.,
1991). For Fgf10 and FgfR2iiib, tissues were frozen in
Tissue-Tek O.C.T. compound (Sakura Finetek, USA, Inc.,
Torrence, CA) and frozen sections were fixed in 2%
paraformaldehyde. For p63, paraffin-embedded sections
were heat treated in a Deloaker pressure cooker (Biocare
Medical, Walnut Creek, CA) in 0.1 M citrate buffer, pH 6.0.
Sections were next blocked with 2% serum and incubated
overnight at 48C with goat anti-Fgf10 antibody (1:100, sc-
7375; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), goat
anti-FgfR2iiib antibody (1:200, sc-122; Santa Cruz), or
rabbit anti-p63 antibody (1:500, sc-8343; Santa Cruz). The
sections were reacted with biotinylated anti-IgG (Vector
Laboratories, Inc., Burlingame, CA) and detected with
avidin–biotin peroxidase (ABC-Elite, Vector Laboratories)
using diaminobenzidine tetrachloride (DAB) as chromagen.
For controls, normal goat or rabbit IgG was substituted for
primary antibody. The sections were counterstained with
Gill’s #3 hematoxylin (1:4).
ICC was used to localize BrdU-labeled cells from organ
culture studies according to the method of McGinley et al.
(2000). Paraffin blocks were sectioned along the longi-
tudinal axis of the gland, sections (5 Am) were hydrolyzed
in 2 N HCl for 90 min, and endogenous peroxide was
blocked with 3% H2O2. Sections were incubated with
Table 1
Primers and Taqman probes used for RT-PCR
Gene Sequence GenBank
GI #
Amplicon
size (bp)
Fgf10
Forward primer cgtcaaagccattaacagca 6978836 107
Reverse primer cctctatcctctctttcagtttacagt
Probe tgagccatagagtttccccttcttgttc
FgfR2iiib
Forward primer gacgtagaatttgtctgcaagg 11139011 81
Reverse primer actgccgttcttttccaca
Probe atagtgatgcccagccccatatcca
Shh
Forward primer caattacaaccccgacatca 8394266 142
Reverse primer agtcactcgaagcttcactcc
Probe ctctgagtcatcagccggtctgctc
ptc1
Forward primer tcacagagacagggtacatgg 4092049 104
Reverse primer cccggactgtagctttgc
Probe ccttcccagaagcagtccaaaggtg
Bmp4
Forward primer gattggctcccaagaatcat 6978570 114
Reverse primer cctagcaggacttggcataa
Probe cgaccatcagcattcggttaccag
Bmp7
Forward primer agtgtgccttccctctgaac 3337107 99
Reverse primer agggcttgggtacggtgt
Nkx3.1
Forward primer ccgagtctgatgcacatttt 2105349 95
Reverse primer ctgtggctgcttggtgac
Hoxb13
Forward primer gatgtgttgccaaggtgaac 6680246 83
Reverse primer gaggagggtgctggacac
Probe aaagcagcgtttgcagagcc
Rpl19
Forward primer ggaagcctgtgactgtccat 14389296 101
Reverse primer ggcagtacccttcctcttcc
Probe aagggcaggcatatgggcat
Designed using the following websites: http://www.bioinfo.rpi.edu/
applications/mfold/old/dna/, http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi.
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antibody (Vector Laboratories), and detected with avidin–
biotin peroxidase using DAB as a chromagen followed by
counterstain with Harris hematoxylin. Labeled epithelial
cells in the proximal and centro-distal ducts were counted
using Zeiss Image ver. 3.0 software and a proliferation
index was determined by calculating the number of
positively labeled epithelial cells per square micrometer
multiplied by 1000. Ducts in the glandular area closest to
the urethra that had not yet branched were considered
proximal ducts. The remainder of the gland was considered
centro-distal ducts.
Real-time RT-PCR
Two procedures were used for RNA extraction and
reverse transcription (RT) depending upon tissue volume. A
standard assay for pnd 6–90 VP involved RNA extraction
with Trizol (Invitrogen), DNase I digestion (Roche), and RT
with AMV at 428C for 60 min using the RT System
(Promega, Madison, WI). For smaller tissues (pnd 1–6 VP,
pnd 3–10 LP and DP, and cultured prostate lobes), a RNeasy
Kit (Qiagen, Valencia, CA) was used for RNA extraction,
On-Column DNase I digestion, and RTwith MMLVat 378C
for 60 min using First Strand cDNA Synthesis Kit
(Fermentas Inc., Hanover, MD). Random primers were
used for reverse transcription.
Real-time PCR was performed in duplex with Platinum
qPCR Supermixture-UDG (Invitrogen) using an iCycler
(Bio-Rad, Hercules, CA). Reaction conditions were opti-
mized for each gene and the cycle conditions were 958C for
3 min and 40 cycles of 958C for 15 s and 608C for 30 s. The
exon-spanning primers and dual-labeled probes are listed in
Table 1. For dual-labeled probes, 5V-reporters were FAM for
Fgf10, FgfR2iiib, Shh, Bmp4 and Hoxb13; Hex for ptc and
Rpl19; and the 3V-reporter was labeled with black hole
quencher. SYBR green assay was performed for Bmp7 and
Nkx3.1, and melting curve analysis confirmed the product
specificity. Plasmids containing each DNA sequence
(Fgf10, FgfR2iiib, Shh, ptc1, Bmp4, Hoxb13, and Rpl19)
were cloned with TOPO TA cloning kit (Invitrogen) and
used for standard curves in each reaction to directly
quantitate target DNA levels. Ribosomal Protein L19
(Rpl19) was quantitated and served as an internal reference
for normalization. Direct comparisons of Rpl19 per unit
total RNA revealed no effect of estrogen treatment in
developing prostates. Optical data obtained by real-time
PCR were analyzed with the manufacturer’s software
(iCycle Optical System Interface ver. 3.0). Each assay was
repeated 3–10 times using different tissues.
Statistical analysis
Tissue 2D area, BrdU labeling, and RT-PCR results were
analyzed by two-tailed Student’s t test (2 group compar-
isons) or, for multiple groups, analysis of variance followedby Bonferroni’s post hoc tests (Instat ver. 3.01, GraphPad
Software, Inc., San Diego, CA).Results
Fgf10 and FgfR2iiib in the developing rat prostate
Whole mount ISH and real-time RT-PCR were used to
examine the spatial and temporal expression patterns of
Fgf10 and FgfR2iiib in the developing rat prostate lobes
during the active period of branching morphogenesis.
While the spatial expression patterns were similar between
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genes in the DP and LP was shifted 2–3 days later than the
more rapidly developing VP. On pnd 1, the earliest time
point examined in this study, the unbranched DP and LP
epithelial buds were beginning to penetrate the prostatic
mesenchyme while the VP ducts had elongated into the
mesenchymal pad and dichotomous branching had begun.
At this time, there was broad expression of Fgf10 mRNA
in the DP and LP distal mesenchyme while the penetrating
epithelial buds were negative, providing a punched-hole
appearance to the ducts (Fig. 1A). In the VP, Fgf10
expression was also greatest in the distal mesenchyme and
had begun to localize most intensely to the condensed
mesenchyme surrounding the distal aspects of the elongat-
ing and branching ducts. By pnd 3, this localization pattern
was also evident in DP and LP ducts (Fig. 1B). By pnd 6,
the intensity of the Fgf10 signal had declined and was
primarily localized to the periductal mesenchyme in all
lobes (Fig. 1C). Microdissection of a VP sublobe (Fig. 1G)
and distal tip (Fig. 1I) from a pnd 6 prostate permitted clear
demonstration of the distal concentration of this morphogen
in the condensed mesenchyme immediately adjacent to the
elongating and branching epithelial ducts. Quantitation of
absolute levels of Fgf10 mRNA by real-time RT-PCR over
time confirmed that the highest expression in the VP was at
pnd 1 and levels declined thereafter to a nadir at day 30Fig. 1. Whole mount ISH for Fgf10 (A, B, C, G, and I) and FgfR2iiib (D, E, F, H,
different days were processed together to allow direct comparisons of signal stre
mesenchyme, whereas in the VP, mesenchymal Fgf10 has begun to coalesce in the
aspects of the gland. At pnd 3 (B), intense Fgf10 expression is observed in the di
ducts. By pnd 6 (C), Fgf10 mRNA signal intensity has declined and is localiz
branching ducts. A dissected pnd 6 VP sublobe (G) and distal tip (I) confirms t
contrast, FgfR2iiib expression was confined to the epithelial cells in the central-
distal tips from pnd 1 to 6 (D–F). A dissected pnd 6 VP sublobe (H) and distal tip (
most intense signal at the distal tips of the elongating and branching ducts. Each tis
prostate, LP = lateral prostate. Scale bar = 200 Am.where they remained through adulthood (Fig. 2A, solid
circles). DP and LP levels were quantified during the early
developmental periods and total prostatic levels held steady
between pnd 3 and 10 in those regions. Testosterone
exposure for 18 h did not influence Fgf10 transcript levels
in either the VP or LP during the developmental period
(Fig. 2B).
As a counterpart to its secreted ligand, FgfR2iiib
expression was confined to epithelial cells in the distal
regions of the elongating and branching ducts in all
prostate lobes between pnd 1 and 6 (Figs. 1D–F).
Microdissection of a pnd 6 VP sublobe (Fig. 1H) revealed
lack of proximal duct FgfR2iiib mRNA and an increasing
expression gradient along the central–distal axis with the
highest signal at the distal tips. Further, a dissected VP
distal tip (Fig. 1J) and cross-sectional analysis (data not
shown) confirmed the strict epithelial localization of this
receptor. Quantitation of FgfR2iiib mRNA levels in the
separate lobes by real-time RT-PCR revealed that VP
expression levels were highest at pnd 3, and declined
thereafter to a nadir at day 30 where they remained (Fig.
2). Similarly, DP and LP total FgfR2iiib expression
declined significantly by pnd 10 as compared to pnd 6.
Exposure to testosterone for 18 h did not affect FgfR2iiib
mRNA levels in either the VP or LP during the
developmental period (Fig. 2B).and J) in the developing rat prostate gland. For each probe, the tissues on the
ngth. On pnd 1 (A), Fgf10 mRNA is broadly expressed in the DP and LP
condensed mesenchyme surrounding the elongating ductal buds in the distal
stal regions of all lobes and is approximate to the elongating and branching
ed strictly to the condensed mesenchyme surrounding the elongating and
he distal and periductal Fgf10 expression in the prostatic mesenchyme. In
to-distal regions of the elongating ducts with the greatest expression at the
J) confirm that FgfR2iiib is expressed exclusively in the epithelium with the
sue is representative of 3–5 experiments. VP = ventral prostate, DP = dorsal
L. Huang et al. / Developmental Biology 278 (2005) 396–414402Fgf10 promotes prostatic ductal elongation and branching
and enhances epithelial differentiation
To further clarify the roles for Fgf10 in prostate
development, several organ culture experiments were
performed. VP and LP prostate lobes were removed onpnd 0 and cultured for 6 days in testosterone with or without
exogenous Fgf10 protein. For both lobes, the addition of
Fgf10 enhanced prostatic growth and led to a cystic
appearance at the distal tips of the prostatic ducts (Fig.
3A). This resulted in a modest increase in lobe area that was
significant for the LP only (Fig. 3B). However, it is
important to note that testosterone and endogenous Fgf10
were present in both culture groups. Cross-sectional analysis
of the cultured tissues confirmed that the Fgf10-treated
ducts were wider than the controls (Fig. 3D) at the
nonlumenized distal aspects and were filled with cells
(Fig. 3E), suggesting increased epithelial cell number as a
result of Fgf10 treatment. This was confirmed by BrdU
labeling that revealed that epithelial proliferation rates in the
central–distal ducts of the Fgf10-treated LPs were signifi-
cantly higher than testosterone controls (Fig. 3C). In
contrast, proliferation rates in the proximal ducts were
unaffected by Fgf10 exposure. It is noteworthy that the
increased epithelial proliferation was confined to the
central–distal ductal regions where FgfR2iiib is present,
implicating a direct effect of Fgf10 on epithelial cell
proliferation.
Evidence was also observed for the enhancement or
acceleration of prostatic epithelial differentiation by Fgf10.
Prostate sections from the above cultures in testosterone
with or without Fgf10 were labeled for basal cells using
p63 and examined histologically. In LPs cultured in
testosterone for 6 days, nonlumenized ducts were lined
with a continuous layer of basal cells along the basement
membrane and solid cords of early differentiating lumenal
cells were piled above (Figs. 3D and F). In LPs cultured
with testosterone plus Fgf10, the proximal–central ducts
were consistently lumenized with differentiated columnar
epithelium positioned above the basement membrane
(Figs. 3E and G).
To directly examine the role of Fgf10 on ductal
elongation and branching, mesenchyme-free prostatic ducts
were isolated from the distal portion of the VP on pnd 0 and
cultured for 44 h in growth factor-reduced Matrigel in theFig. 2. (A) Ontogeny of Fgf10 and FgfR2iiib mRNA expression in the rat
prostate lobes as quantitated by real-time RT-PCR. Fgf10 (solid circles)
expression in the VP was high at birth and significantly declined thereafter
reaching a nadir by pnd 30 where it remained through adulthood. Fgf10
expression levels in the LP and DP in the early developmental stage are
comparable with the levels in the VP. FgfR2iiib (open circles) expression
level peaked at pnd 3 in the VP and declined quickly thereafter reaching a
stable low level at pnd 30. For DP and LP, FgfR2iiib expression
significantly declined by pnd 10 despite the fact that the epithelial cell
number, where the receptor is expressed, was concomitantly increasing.
Points represent meanF SEM for 3–10 replicates. For VP Fgf10 level: #P b
0.05 vs. pnd 1, ##P b 0.01 vs. pnd 1. For VP FgfR2iiib level: **P b 0.01
vs. pnd 3, ***P b 0.001 vs. pnd 3. For LP and DP FgfR2iiib level: *P b
0.05 vs. pnd 6, **P b 0.01 vs. pnd 6. (B) Effect of testosterone (T) on
Fgf10 and FgfR2iiib mRNA expression in early prostate development. VPs
and LPs were cultured for 20 h in the presence or absence of 10 nM
testosterone. No significant differences in Fgf10 or FgfR2iiib transcript
levels were detected in either lobe. Bars represent mean F SEM for eight
replicates.
Fig. 3. Cultured VP and LP following application of Fgf10 or BSA. Paired lobes from a single rat were treated with either BSA or Fgf10 to allow direct
comparison of Fgf10 treatment. (A) VPs (top) and LPs (bottom) cultured for 6 days in the presence of testosterone (T) and either BSA (left) or Fgf10 protein.
Fgf10 addition enhanced ductal growth in both lobes and led to a cystic appearance at the distal ductal tips. (B) Growth index of VPs and LPs cultured for 6
days in the presence of T or T + Fgf10. 2D area on day 6 was normalized to day 0 area and bars represent the mean F SEM of six replicates. While Fgf10
treatment augmented growth in both lobes, the difference was significant for the LP only (*P b 0.05). (C) Epithelial cell BrdU labeling index in LP cultured for
6 days with T alone or T + Fgf10. The bar represents the mean F SEM of seven replicates. Proliferation was similar in the proximal ducts in both treatment
groups whereas Fgf10 significantly (*P b 0.05) increased epithelial proliferation in the central–distal ducts. (D–G) Immunocytochemistry for p63 (basal cell
marker) in LPs cultured for 6 days in T alone (D and F) or T + Fgf10 (E and G). Images in F and G are high power views of boxed areas in D and E,
respectively. In LPs cultured in T alone, nonlumenized ducts throughout the lobe were lined with a continuous basal cell layer along the basement membrane
and early differentiating lumenal cells filled the ducts (D and F). In LPs cultured in T + Fgf10 (E and G), ductal elongation and branching were more extensive
than in T alone and lumen diameters appeared thicker. In addition, lumenization in the proximal ducts was consistently observed (E) and epithelial
cytodifferentiation in those regions was complete with short columnar lumenal cells containing basally located nuclei and supranuclear clears zones positioned
above an intermittent layer of p63-stained basal cells (G). Scale bar in A = 500 Am; in D–G = 50 Am.
L. Huang et al. / Developmental Biology 278 (2005) 396–414 403presence of testosterone or Fgf10. Ducts grown in the
presence of testosterone alone slowly balled up over the
course of 44 h and exhibited no clefting, branching, or
elongation, proving an absolute requirement of paracrine
growth factors for this activity (Fig. 4A). Addition of 0.5 Ag/
ml Fgf10 to the medium increased ductal clefting and
budding within 20 h and resulted in ductal elongation and
increased thickness after 44 h (Figs. 4B,C). A dose response
to exogenous Fgf10 was examined with increasing dosesfrom 1 ng to 1 Ag/ml, and effects on branching were not
observed below 0.1 Ag/ml (data not shown). FgfR2iiib is a
receptor tyrosine kinase that acts through the ras/raf/Mek
pathway as well as the PLCg/DAG/Ca++ pathways. To
determine which pathway may be mediating prostatic ductal
growth and budding, prostatic ducts were incubated with
Fgf10 + U0126, a Mek inhibitor, and a complete blockade
of Fgf10-induced budding and elongation was consistently
observed (Fig. 4D). Thus, these results confirm that Fgf10
Fig. 4. Mesenchyme-free VP ductal cultures at 0, 20, and 44 h in the
presence of 108 M testosterone (T), 0.5 Ag/ml Fgf10, or 0.5 Ag/ml Fgf10 +
20 AM U0126. With T alone (A), ducts slowly balled up over the course of
44 h and exhibited no growth. With Fgf10 addition (B and C), the ducts
exhibited increased clefting and budding within 20 h. Ductal elongation and
increased thickness, but no further budding was observed at 44 h. Addition
of Mek inhibitor U0126 completely blocked the Fgf10-induced budding
and elongation (D). Scale bar = 200 Am.
L. Huang et al. / Developmental Biology 278 (2005) 396–414404plays a direct role in stimulating prostatic duct elongation
and branching that is mediated through the ras/raf/Mek
pathway.
Fgf10 regulates the expression of prostatic morphogens and
homeobox genes
To determine downstream genes of Fgf10 in the
prostate gland, pnd 0 VPs were cultured for 24 h in the
absence or presence of Fgf10 and the expression of several
known prostatic morphogens and homeobox genes was
quantified by real-time RT-PCR. Since we recently showed
that Shh downregulated prostatic Fgf10 within 18 h (Pu et
al., 2004), we first examined whether Fgf10 in turn affects
Shh expression to form a feedback loop. As shown by
wmISH (Figs. 5A–B) and RT-PCR (Fig. 5C), Fgf10
significantly upregulates epithelial Shh expression within
24 h. Further, the mesenchymal Shh receptor ptc was also
upregulated by Fgf10 exposure, most likely mediated
through elevated levels of the secreted Shh, a known
inducer of its receptor. In addition, Bmp4, a prostatic
mesenchymal gene upregulated by Shh (Pu et al., 2004),
was significantly repressed following Fgf10 treatment. Theexpression of FgfR2iiib was not affected by Fgf10
treatment, thus autoregulation of its cognate receptor is
not an action of Fgf10 in the prostate gland. Bmp7, a
secreted epithelial morphogen (Huang et al., 2003), was
markedly upregulated by Fgf10 within 24 h. Further, two
epithelial homeobox genes known to be involved in
prostate epithelial differentiation, Nkx3.1 and Hoxb13,
were rapidly upregulated following Fgf10 exposure. These
data strongly implicate Fgf10 as an important regulator of
growth factor networks and homeobox genes critical for
prostate branching morphogenesis and differentiation.
Neonatal estradiol exposure suppresses Fgf10, FgfR2iiib,
and Bmp7 in a lobe-specific manner
We previously determined that neonatal exposure to
estradiol results in lobe-specific phenotypes with greater
branching deficiencies in the LP and DP and a high
incidence of adult-onset dysplasia in the VP (Prins, 1997;
Pu et al., 2004). Furthermore, we recently demonstrated that
the DP/LP branching deficiencies were due, in part, to lobe-
specific reduction in Shh-ptc-gli expression (Pu et al.,
2004). In the present study, exposure to estradiol on pnd 0,
3, and 5 similarly reduced Fgf10 and FgfR2iiib in the LP
and FgfR2iiib in the DP but had no effect on the expression
of these two genes in the VP. As early as pnd 1, wmISH
consistently revealed suppression of FgfR2iiib in the LP
regions whereas Fgf10 suppression was noticeable by pnd 3
when tissues from control and estrogen-treated rats were
processed together (Figs. 6A–D) while gene expression was
similar between the two groups in the VP. The suppression
of Fgf10 and FgfR2iiib expression in the LP and to a lesser
extent the DP persisted through pnd 6 and correlated with a
blunting of ductal elongation and branching in those regions
(Figs. 6E and F). These findings were quantitatively
corroborated by real-time RT-PCR that revealed no differ-
ences between treatment groups for Fgf10 and FgfR2iiib
mRNA levels in the VP between pnd 1–90 (Fig. 7A). In
contrast, LP expression of Fgf10 was significantly lower at
pnd 3 and 6, and FgfR2iiib was markedly reduced at pnd 6
and 10 in estrogen-treated rats as compared to controls (Fig.
7C). In the DP, Fgf10 expression was not affected by
estrogen exposure but FgfR2iiib was significantly reduced
at pnd 6 and 10 (Fig. 7B). Thus, Fgf10 signaling is
disrupted in both the DP and LP lobes following estro-
genization with the greatest impact observed in the LP.
Since the two genes are expressed in different tissue
compartments, altered ratios of stroma/epithelium following
neonatal estrogen exposure cannot account for the decline in
expression of both genes.
Immunocytochemistry was used to examine the Fgf10
and FgfR2iiib protein levels in the developing LP and VP
following estrogen treatment, and the findings correlated
with the transcript levels. In the control LP and VP, Fgf10
protein localized to the stroma in the distal aspects of the
glands as well as the epithelial cells where it is known to
Fig. 5. The effects of Fgf10 on prostatic gene expression. (A) Whole mount ISH of Shh mRNA in the pnd 0 UGS–prostatic complex following culture for 24 h
in BSA (left) or 0.5 Ag/ml Fgf10 (right). Samples shown were processed together to allow direct comparison of signal intensity. Fgf10 significantly upregulated
epithelial Shh expression in the VP and LP ducts within 24 h. Scale bar = 200 Am. (B) A higher power view of VPs from a replicate set of tissues exposed to
BSA (left) or 0.5 Ag/ml Fgf10 (right) for 24 h followed by wmISH for Shh mRNA. Shh signal intensity is visibly higher in the distal tips of VP ducts following
Fgf10 exposure. Both VPs were processed together to allow direct comparison of signal intensity. Scale bar = 200 Am. (C) Gene expression as determined by
real-time RT-PCR from contralateral VPs (n = 8) cultured in the presence of BSA (open bars) or 0.5 Ag/ml Fgf10 protein (solid bars) for 24 h. The mRNA level
for each gene following Fgf10 exposure is expressed relative to BSA control levels (determined as 1) following initial quantitation and normalization to Rpl19
levels. Fgf10 significantly increased epithelial Shh and mesenchymal ptc expression, suppressed mesenchymal Bmp4 expression, and markedly increased
epithelial Bmp7, Nkx3.1, and Hoxb13 expression as compared to BSA controls. The expression of FgfR2iiib expression was not altered by Fgf10 treatment.
Bars represent the mean F SEM for eight replicates. *P b 0.05, ***P b 0.001, Fgf10 vs. BSA controls.
L. Huang et al. / Developmental Biology 278 (2005) 396–414 405bind to its receptors (Figs. 8A and C). Following estrogen
treatment, there was a marked decline in Fgf10 protein in
the LP (Fig. 8B), whereas protein staining in the VP was
equivalent to that observed in oil-treated controls (Fig. 8D).
FgfR2iiib was initially localized to the cytoplasm of
undifferentiated prostate epithelial cells on days 1 and 3
(data not shown), and additional immunostain was observed
in the epithelial cell nuclei of the LP and VP by pnd 6 (Figs.
8E and G). This immunostain was reduced in intensity
throughout the DP and LP ducts following estrogen
exposure (Fig. 8F) but was unaltered by hormone treatment
in the VP (Fig. 8H).
Since the above findings showed that Bmp7 is down-
stream of Fgf10 in the prostate, we examined the response
of this gene to Fgf10 and FgfR2iiib downregulation
following estrogen exposure as a functional marker for
Fgf10 action. Bmp7 was localized by wmISH to epithelial
cells in the distal tips of the elongating ducts on pnd 1, and
its expression markedly increased by pnd 3 as the ducts
entered the active phase of branching morphogenesis (Figs.
9A–C). Following neonatal estradiol exposure, Bmp7
expression was significantly suppressed in the DP and LP
lobes but was not affected in the VP as revealed by wmISH(Figs. 9A and B) and real-time RT-PCR analysis (Fig. 9D).
This lobe-specific Bmp7 suppression that mirrors the
decrease in Fgf10/FgfR2iiib expression in the DP and LP
suggests that downregulation of Fgf10 signaling may be the
proximate cause of estrogenized defects in the dorsolateral
lobe.
Direct effects of estradiol on Fgf10 and FgfR2iiib
expression
To determine whether the effects of estradiol on
prostatic Fgf10 and FgfR2iiib expression were direct
prostatic effects or indirectly mediated through systemic
alterations following estrogen treatment, an organ culture
system was employed for the developing LP. On the day
of birth, LPs were removed from the prostatic/UGS
complex and grown in vitro with testosterone or testoster-
one plus 20 AM estradiol (contralateral lobes). As shown
in Fig. 10A, the LP ductal growth and branching that
occurred in the presence of testosterone over 6 days were
markedly suppressed by the addition of estradiol, indica-
ting that the estrogen effects were directly mediated at the
prostatic level. Furthermore, measurement of Fgf10 and
Fig. 6. Whole mount ISH (wmISH) for Fgf10 (A–C) and FgfR2iiib (D–F) expression in the UGS–prostatic complexes from control and estrogen-exposed rats.
Treated tissues for each probe were processed and photographed together to allow direct comparisons of signal intensity between treatment groups. (A) Fgf10
message in pnd 1 oil (left) and estradiol-treated (right) rats. Mesenchymal Fgf10 signal intensity was lower in estrogen-exposed LPs as compared to oil-treated
controls while the signal in the VPs appeared unaffected. (B and C) Fgf10 transcript in pnd 3 (B) and pnd 6 (C) prostates from rats treated with oil (left) or
estradiol (right). Mesenchymal Fgf10 expression in the distal regions of the LPs was markedly suppressed by estrogen exposure as compared to oil-treated
controls while expression in the VP was unaffected. (D) FgfR2iiib transcript in pnd 1 complexes from control (left) and estrogen-treated rats (right). Signal
intensity for FgfR2iiib transcript at the distal tips of elongating ducts was markedly reduced in the estrogen-exposed LP and DP as compared to controls while
VP expression appeared minimally affected by estrogen treatment. (E and F) FgfR2iiib wmISH in pnd 3 (E) and 6 (F) prostatic complexes from control (left)
and estrogen-exposed rats (right). Ductal growth, branching, and FgfR2iiib expression were markedly reduced in the LPs and DPs of rats exposed to estradiol
as compared to controls while VP expression remained unaffected. Each tissue is representative of 3–5 experiments. Scale bar = 200 Am.
L. Huang et al. / Developmental Biology 278 (2005) 396–414406FgfR2iiib transcript levels in cultured LPs by real-time RT-
PCR showed a significant reduction in the expression of
both genes, indicating that altered expression of these
genes is a direct result of estrogen exposure (Fig. 10B).
The reduction in epithelial FgfR2iiib expression was
visualized by wmISH (Fig. 10C), where DLP, but not
VP, signal was markedly lower following culture in
estradiol.
Fgf10 restores ductal growth and branching in LPs exposed
to estradiol in vitro
To determine whether reduced prostatic Fgf10 signal-
ing mediates the suppression of LP branching morpho-genesis in response to estrogen exposure, organ culture
experiments were undertaken with exogenous Fgf10
replacement. LPs were removed on the day of birth
and cultured with testosterone (T), testosterone plus 20
AM estradiol (T + E2), or testosterone plus estradiol and
0.5 Ag/ml Fgf10. As shown in Fig. 11A, LPs cultured in
the presence of estradiol (T + E2) showed marked
inhibition of ductal elongation and branching as com-
pared to LPs cultured in the presence of testosterone
alone. The addition of Fgf10 to the T + E2 culture fully
rescued LP growth and branching, which were confirmed
by measurement of prostatic area (Fig. 11B). Histological
examination revealed stunted epithelial ducts filled with
undifferentiated epithelial cells following in vitro estradiol
Fig. 7. Real-time RT-PCR of Fgf10 and FgfR2iiib mRNA levels over time
in the (A) VP, (B) DP, and (C) LP of control (open bars) and estrogen-
exposed rats (solid bars). Expression of both genes in the VP at all time
points was not influenced by neonatal estrogen exposure. Estrogen
exposure resulted in a significant decrease in Fgf10 expression in the LP
at pnd 3 and 6, and a significant decrease in FgfR2iiib expression in the LP
and DP at pnd 6 and 10. Bars represent the mean F SEM for 3–10
replicates per treatment and time point. *P b 0.05, **P b 0.01, ***P b
0.001 estrogen-treated vs. controls at specific time points.
L. Huang et al. / Developmental Biology 278 (2005) 396–414 407exposure (Fig. 11C). The addition of Fgf10 to the T + E2
culture reversed the estrogen suppression of cellular
differentiation and LPs resembled those cultured in
testosterone alone or testosterone + Fgf10 (Figs. 3D–G).
Taken together, these data provide compelling evidence
that Fgf10 and its downstream genes are able to restore
growth and branching to estrogen-exposed LPs and support
the hypothesis that alterations in the Fgf10/FgfR2iiib
pathway are involved in mediating the estrogenized
phenotype.Discussion
Fgf10 and FgfR2iiib localize to the distal signaling center in
the developing rat prostate lobes
The present study provides a clear spatiotemporal
picture of the expression patterns of Fgf10 and FgfR2iiib
in separate rat prostate lobes during development. As has
been previously described for the rat VP (Thomson and
Cunha, 1999), Fgf10 is broadly expressed in distal
mesenchymal cells of all lobes as prostatic buds emerge
from the UGS at the time of birth. As the ducts elongate
and make contact with this Fgf10 expression domain, the
pattern shifts such that the highest expression is observed
in the condensed mesenchyme immediately surrounding
the distal ducts while interductal Fgf10 expression
declines. In this manner, Fgf10-expressing cells make
direct contact with the basement membrane ECM sur-
rounding the elongating epithelial ducts at the time when
branching commences. This was substantiated by immu-
nolocalization of the secreted Fgf10 protein that was
observed in the distal periductal mesenchyme and along
the basal aspects of the ductal epithelium where it is
known to ligand to its receptor FgfR2iiib. This shift to a
periductal expression pattern occurs ~2 days later for the
DP and LP than for the VP, consistent with the known
time delay in branching morphogenesis for these more
anterior lobes (Hayashi et al., 1991).
Previous reports on the localization of FgfR2iiib have
shown that it is exclusively expressed by prostatic
epithelium, thus establishing the paracrine nature of this
morphoregulatory signal (Finch et al., 1995). In the present
study, we characterize this further through the use of
wmISH and ICC, and demonstrate that FgfR2iiib is
localized to the far centro-distal region of the elongating
and branching ducts and is absent in the proximal and
initial central prostatic ducts. Thus, similar to Shh in the
developing prostate (Pu et al., 2004), Fgf10 action through
FgfR2iiib is highest in the distal signaling center at the
ductal tips during the active phase of branching morpho-
genesis. This regionalized paracrine function for Fgf10 is
supported by BrdU labeling results following exogenous
Fgf10 exposure where epithelial cell proliferation increases
in the centro-distal ducts while no additional proliferative
response is noted in the proximal ducts. As branching
morphogenesis nears completion in separate lobes
(between days 6 and 15), expression levels for Fgf10 or
FgfR2iiib decline, reaching their nadir at day 30 where
they remain through adulthood confirming the primary role
for this morphoregulatory factor in the developmental
process.
While initial studies indicated that Fgf10 expression was
upregulated by testosterone in prostatic stromal cells in vitro
(Lu et al., 1999), organ culture studies indicated that
androgen regulation of Fgf10 mRNA levels was nominal
after 4 days of exposure (Thomson and Cunha, 1999). In the
Fig. 8. Immunocytochemistry of Fgf10 and FgfR2iiib protein in rat prostate at pnd 6. (A–D) Fgf10 protein in control (left) and estrogen-treated (right) LPs and
VPs. In the control LP (A) and VP (C), Fgf10 protein localized to both mesenchymal cells (m, arrows) and the basal surface of epithelial cells (e, arrowheads)
in the distal aspects of the glands. Following estrogen exposure, Fgf10 immunostaining was reduced in the LP (B) while protein staining in the VP was similar
to that observed in the oil-treated controls (D). Inserts in A and D show normal goat-IgG-negative controls. (E–H) FgfR2iiib protein in the distal tips of control
(left) and estrogen-treated (right) LPs and VPs. In the control LP (E) and VP (G), FgfR2iiib localized to epithelial cells in the distal aspects of the glands.
Occasional stromal cells immunostained positive; however, this appeared in the normal goat-IgG-negative controls (E, inset), suggesting nonspecificity.
Following estrogen exposure, FgfR2iiib immunostain was reduced in the LP (F) while the protein staining in the VP was similar to that observed in oil-treated
controls (H). Scale bar = 50 Am.
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whole prostate Fgf10 transcript levels prior to changes in
cellular composition as a result of androgen exposure. We
find that testosterone has no effect on Fgf10 expression in
the rat VP or LP within 20 h of exposure, which confirmsthat this is not an androgen-regulated gene in the prostate in
situ. Furthermore, we demonstrate that testosterone does not
affect FgfR2iiib expression, which, in total, indicates that
androgens do not directly affect Fgf10 signaling in the
developing prostate gland.
Fig. 9. Bmp7 expression in the developing prostate. (A) Whole mount ISH for Bmp7 in the UGS–prostatic complexes from control (left) and estrogen-exposed
rats (right) on pnd 1. An image of the dorsolateral region is shown in the top panel, while VPs from the same tissue are shown in the bottom panel at a separate
focal plane. Both tissues were processed together to allow direct comparisons of signal intensity. Bmp7 transcript is localized to the distal tips of the ducts and is
visibly suppressed in the DLP but not the VP by estrogen exposure. Scale bar = 200 Am. (B) Bmp7 transcript in pnd 3 prostates from rats treated with oil (left)
or estradiol (right). The Bmp7 signal is more intense in all lobes of the pnd 3 control rat as compared to pnd 1. In the estrogen-treated rat, the LP (top) signal is
reduced while the VP (bottom) signal is similar to that observed in control tissues. The tissues in A and B were processed together to allow direct comparison of
signal intensity and this result was repeated five times. Scale bar = 200 Am. (C) Cross-section wmISH shows the epithelial localization of Bmp7 at the distal tips
of the VP. E = epithelial, M = mesenchyme. Scale bar = 50 Am. (D) Real-time RT-PCR of Bmp7 on pnd 6 of control (open bars) and estrogen-exposed rats
(solid bars). Estrogen significantly reduced Bmp7 expression in the DP and LP while VP expression levels were unaffected. Bar represents the meanF SEM of
7–10 replicates. *P b 0.001, estrogen-treated vs. controls.
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proliferation, and differentiation
Previous studies with rodents have shown an essential
role for Fgf10 in both prostatic bud induction (Donjacour
et al., 2003) and ductal branching (Thomson and Cunha,
1999). The present study confirms and extends this later
role for Fgf10 during prostate development. We observe
that exogenous Fgf10 augments testosterone-induced pro-
static growth in LP and, to a lesser degree, VP organ
cultures by increasing epithelial cell proliferation in the
distal but not proximal ductal regions. In this system, the
terminal ducts appear cystic, which may be related to the
uncontrolled availability of exogenous Fgf10 that can lead
to growth and branching distortions, as was previously
noted in the lungs (Cardoso, 2000). Our mesenchyme-free
ductal culture studies demonstrate a direct role for Fgf10
in prostatic ductal elongation and branching. While
testosterone alone is incapable of inducing ductal clefting
or elongation in VP distal ducts grown in growth factor-
reduced Matrigel, Fgf10 alone stimulates ductal clefting
and branch points within 20 h and drives ductal elongation
thereafter. In addition, inhibition of this process by a
specific Mek inhibitor indicates that these activities of
Fgf10 are mediated through the ras/raf/Mek pathway andnot through the alternate PLCg/DAG/Ca++ pathway
(Szebenyi and Fallon, 1999). Together, these findings
prove that Fgf10 is capable of directly initiating branch
points and stimulating elongation of prostatic ducts.
However, ductal branching to the full extent observed in
vivo was not recapitulated with Fgf10 in vitro, which
suggests that other growth factor pathways such as Shh
(Pu et al., 2004) and Bmp7 (see below) are required for
complete branching morphogenesis.
The organ culture studies also provide evidence that Fgf10
may be involved in prostate epithelial cell differentiation.
Prostates grown in the presence of testosterone plus Fgf10
exhibited accelerated ductal lumenization and columnar
epithelial cell differentiation as compared to lobes cultured
in the presence of testosterone alone. Studies with the lung
have shown a similar role for Fgf10 in epithelial differ-
entiation in addition to its role as an inducer of branching
(Cardoso, 2001; Peters et al., 1994). It is noteworthy that
Fgf10 rapidly and significantly upregulated expression of
Nkx3.1 and Hoxb13, two homeobox genes preferentially
expressed by the prostate epithelium that are involved in
epithelial differentiation (Bhatia-Gaur et al., 1999; Econo-
mides and Capecchi, 2003; Prins et al., 2001a,b). Thus, it is
possible that Fgf10 may influence epithelial differentiation,
in part, through these downstream genes.
Fig. 10. (A) LPs collected on pnd 0 and cultured for 6 days in basal
medium with 108 M testosterone (T) or with testosterone plus 20 AM
estradiol (T + E2). Ductal elongation and branching observed in day 6 T
cultures were suppressed when LPs were cultured in T + E2. Scale bar =
500 Am. (B) Real-time RT-PCR for Fgf10 and FgfR2iiib in the LP after 6
days in culture with T (hatched bars) or T + E2 (solid bars). Bars
represent the mean F SEM for 10 replicates. *P b 0.05, ***P b 0.001, T
vs. T + E2. (C) Whole mount ISH of FgfR2iiib transcript in the pnd 0
UGS–prostatic complex after 40 h of culture. For photographic purposes,
the complex was tilted to allow a clearer view of one side of the LP and
DP. Epithelial FgfR2iiib expression was decreased in the DP and LP
cultured in T + E2 (right) when compared with T alone (left) while
expression in VP is not affected by estrogen treatment. This assay was
replicated three times. Scale bar = 200 Am.
Fig. 11. Fgf10 restores ductal growth and branching in LPs exposed to
estradiol in vitro. (A) LP cultured for 6 days in basal medium with 108 M
testosterone (T), testosterone + 20 AM estradiol (T + E2), and testosterone +
estradiol + 0.5 Ag/ml Fgf10 (T + E2 + Fgf10). Top row, tissues at day 0;
bottom row, tissues after 6 days of culture. LPs cultured in the presence of
estradiol (T + E2) showed marked inhibition of ductal elongation and
branching as compared to LPs cultured in the presence of testosterone alone
(T). The addition of Fgf10 to the T + E2 culture (T + E2 + Fgf10) fully
rescued the LP growth and branching. Scale bar = 500 Am. (B) Prostatic 2D
area in day 6 LPs normalized to day 0 area. Bars represent the meanF SEM
for six replicates. *P b 0.05, T + E2 vs. T + E2 + Fgf10. (C) Tissues from
T + E2 (left) and T + E2 + Fgf10 (right) cultures shown in Awere sectioned
and immunostained for basal cell p63. The images on the bottom are high-
powered views of boxed areas shown above at low power. The LPs cultured
in T + E2 were stunted and nonlumenized ducts were filled with early
differentiated lumenal cells above a continuous layer of basal cells. The
addition of Fgf10 to the T + E2 cultures restored ductal elongation and
branching and lumenized ducts with epithelial cytodifferentiation appeared
in the proximal regions. Scale bar = 50 Am.
L. Huang et al. / Developmental Biology 278 (2005) 396–414410Downstream genes of Fgf10: signaling networks during rat
prostate development
While Fgf10 is known to regulate the expression of
signaling molecules in several developing branched struc-
L. Huang et al. / Developmental Biology 278 (2005) 396–414 411tures (Cardoso, 2001; Haraguchi et al., 2000; Revest et al.,
2001; Szebenyi and Fallon, 1999), downstream targets for
Fgf10 action in the prostate gland have not been previously
defined. Herein we demonstrate that Fgf10 has multiple
downstream genes in the developing rat prostate gland
including other signaling networks and homeobox genes
that position this secreted morphogen as a key regulator of
both prostate branching, growth, and differentiation. Epi-
thelial Shh and its mesenchymal receptor ptc are upregu-
lated by Fgf10 within 18 h of Fgf10 exposure, the later gene
effect most likely being mediated through Shh, which
autoregulates its receptor (Lamm et al., 2002). We have
previously demonstrated that Shh locally downregulates
Fgf10 expression in prostatic mesenchyme (Pu et al., 2004).
As schematized in Fig. 12A, we propose that Fgf10, via
epithelial FgfR2iiib, directly upregulates epithelial ShhFig. 12. (A) A schematic representation of regulatory networks between secreted m
of the developing prostate gland. Fgf10 (mesenchymal) and FgfR2iiib (epithelial) u
branching morphogenesis as well as Hoxb13 and Nkx3.1 involved in epithelial dif
downregulate (red lines) Fgf10 expression, thus establishing a negative feedback lo
Bmp4 molecule in the mesenchyme while Fgf10 downregulates its expression, wh
shows a tentative model for dichotomous branching of the developing rat prostat
factors. The distal signaling center of elongating epithelial buds expresses Bmp7 i
foci (yellow hatched cells only) while the distal mesenchyme expresses Fgf10 (gre
(b), the secreted Shh (red arrow) activates ptc on mesenchymal cells and locally d
expression. The focal downregulation of Fgf10 results in lateral subdomains of h
Bmp4, upregulates epithelial Bmp7 (yellow arrow), and activates (green arrow) hig
proliferation rates in the lateral domains result in the sprouting of two buds on eac
the elevated Fgf10 in the lateral domains upregulates Shh and ptc expression (d),
patterns. The right side of this schematic shows the events following estrogen exp
directly suppresses mesenchymal Fgf10 expression (b) resulting in the inability o
branching is effectively blocked.expression resulting in upregulation of mesenchymal ptc
and glis that downregulate mesenchymal Fgf10 expression,
thus establishing a negative feedback loop that provides
tight control of branching. In the limb bud, Shh was
similarly identified as a downstream target of FgfR2iiib
(Revest et al., 2001); however, in that system, Fgf10 and
Shh were found to induce each other (Ohuchi et al., 1997),
which points out the specificity of growth factor cascades in
different tissues.
The present studies further show that Fgf10 regulates
prostatic expression of Bmp family molecules that have
known roles in branching morphogenesis. In the subman-
dibular gland, Bmp7 works together with Fgf7 and Fgf10 to
promote branching morphogenesis while Bmp4 plays an
opposing role that together control appropriate gland
formation (Hoffman et al., 2002). While a similar role fororphogens in epithelial and mesenchymal cells at the distal signaling center
pregulate (green arrows) epithelial expression of Shh and Bmp7 involved in
ferentiation. Shh upregulates ptc and gli in adjacent mesenchymal cells that
op for controlled growth. Shh-ptc-gli also upregulates the growth inhibitory
ich further serves to tightly control localized tissue growth. (B) The left side
e ducts as controlled by localized expression of secreted morphoregulatory
n all cells (yellow cells including yellow hatched cells) and Shh in discreet
en dots) and Bmp4 (blue dots). As these cells make contact with each other
ownregulates Fgf10 (loss of green dots) and upregulates Bmp4 (blue dots)
igher Fgf10 expression adjacent to the Shh foci that in turn downregulates
her epithelial proliferation via epithelial FgfR2iiib. The disparate epithelial
h side of the Shh foci (blue arrows) that initiates a branch point (d). Further,
which allows repetition of the above steps and results in complex branching
osure once bud initiation and ductal elongation (a) are underway. Estradiol
f cells to form localized morphogen gradients through feedback loops and
L. Huang et al. / Developmental Biology 278 (2005) 396–414412Bmp7 in the prostate gland has not been explored, the
present findings show that Bmp7 is expressed by epithelial
cells in the distal signaling center and expression markedly
increases during the rapid phase of branching morpho-
genesis. Moreover, Fgf10 upregulates prostatic Bmp7
expression, and branching deficits following estrogen
exposure coincide with decreased Bmp7 expression.
Together, these findings suggest a stimulatory role for
epithelial Bmp7 in prostatic branching with direct positive
regulation from mesenchymal Fgf10. In contrast, Fgf10
downregulates expression of Bmp4, an established restrictor
of growth and branching in the prostate gland (Lamm et al.,
2001). Since Fgf10 and Bmp4 have opposing actions with
regards to prostatic ductal outgrowth, localized down-
regulation of Bmp4 expression by Fgf10 may contribute
to Fgf10’s stimulatory effects. Furthermore, since Shh
upregulates mesenchymal Bmp4 expression at focal sites
in prostatic ductal tips (Pu et al., 2004), downregulation by
Fgf10 will contribute to the reciprocal regulation necessary
to sculpture the prostatic form (Fig. 12A). Since FgfR2iiib
is not present on mesenchymal cells, Bmp4 downregulation
by Fgf10 may be mediated through an intermediary signal
cascade. Alternatively, Fgf10 can ligand to FgfR1iiib, a
receptor typically expressed in stromal cells, although little
is known of its localization and expression in the normal
prostate (Foster et al., 1999).
Taken together, we propose that gene regulatory net-
works organize normal prostate development through a
temporal series of reciprocal signals and feedback loops that
tightly regulate proliferation, ductal outgrowth, and branch
point formation. A simplified working model for prostate
branching that incorporates morphoregulatory factors exam-
ined herein and in our previous study (Pu et al., 2004) is
shown in Fig. 12B (left), although it must be emphasized
that several other factors, some characterized, others yet
undefined, will undoubtedly play critical roles in this
process. As prostatic buds emerge from the UGS (a), they
grow toward the distal mesenchyme, perhaps in response to
chemoattraction by Fgf10. The epithelial cells at the distal
signaling center express Shh, highly localized in discreet
foci (Pu et al., 2004), as well as Bmp7, whereas the distal
mesenchyme expresses Fgf10 and Bmp4. When Shh foci in
the elongating ducts make contact with the Fgf10 and
Bmp4-expressing cells (b), Fgf10 is focally downregulated
and Bmp4 is focally upregulated by Shh as previously
described (Pu et al., 2004), which leads to lateral sub-
domains of elevated Fgf10 expression. Within those lateral
subdomains, relatively higher Fgf10 levels downregulate
mesenchymal Bmp4 expression and thus release the Bmp4
brake on ductal outgrowth. At the lateral domains, Fgf10
directly increases epithelial Bmp7 expression and epithelial
cell proliferation via epithelial FgfR2iiib (c). The disparate
epithelial proliferation rates at these lateral domains result in
the sprouting of two buds thus initiating a branch point (c).
Fgf10 at the branching tips increases epithelial Shh (d),
which allows the process to repeat itself thus resulting incomplex branching patterns characteristic of the prostate
gland. In this manner, epithelial–mesenchymal cross-talk via
secreted morphogens and their tightly controlled feedback
loops maintain controlled branching morphogenesis. Impor-
tantly, interruption of this signaling network by altered
expression of Fgf10, Shh, Bmp4, and Bmp7 or their cognate
receptors will result in growth and branching abnormalities.
Suppression of Fgf10 signaling mediates the estrogenized
branching phenotype in the dorsolateral prostate
We previously demonstrated that LP and DP, but not VP,
have severe branching deficits following neonatal estrogen
exposure and that this is related to a lobe-specific
suppression of Shh-ptc-gli in the DLP (Pu et al., 2004).
However, ERa, which initiates the cascade of events
following estrogen exposure, is expressed in prostatic
mesenchymal cells (Prins and Birch, 1997; Prins et al.,
2001a,b), which suggests an intermediary pathway in this
process. The present findings provide several lines of
evidence to implicate Fgf10 as a critical mesenchymal
signal that mediates estrogen-induced branching inhibition
in the DLP. First, Fgf10 is expressed in the same population
of periductal mesenchymal cells where ERa is upregulated
following estrogen exposure (Prins and Birch, 1997), thus
direct regulation is possible. Second, FgfR2iiib is expressed
in the distal epithelium and Fgf10 upregulates prostatic Shh
and Bmp7 expression in those same cells. Third, a parallel
suppression of Fgf10, Shh-ptc-gli, and Bmp7 is observed
specifically in the LP following estradiol exposure while VP
expression of these signaling molecules is unaffected.
Fourth, as demonstrated by organ culture, estradiol sup-
pression of Fgf10 and FgfR2iiib us mediated directly at the
prostatic level. Fifth, and most importantly, Fgf10 replace-
ment rescues the growth and differentiation suppression
induced by estradiol in the LP. This contrasts with the
inability of Shh beads to reverse estrogen-induced growth
inhibition (unpublished data) and the ability of Bmp4
antagonists to only partially reverse estrogen effects (Huang
et al., 2003). Taken together with the above data that Fgf10
is a regulator of prostatic Shh, Bmp4, and Bmp7 expression,
these findings suggest that Fgf10 suppression may be a
proximate cause of the branching phenotype in the LP
following neonatal estrogen exposure. This phenomenon is
graphically represented in Fig. 12B (right).
In the normal developing prostate, ERa expression is
restricted to proximal mesenchymal cells where it may be
involved in maintaining a proximal structure by suppress-
ing proximal expression of Fgf10 and other genes
expressed in the distal prostate. When rats are exposed
neonatally to estrogen, ERa expression is induced in
periductal mesenchymal cells along the ductal length out
to the distal tips in all lobes (Prins and Birch, 1997). We
propose that this may downregulate Fgf10 and other
morphoregulatory genes in the distal signaling center, thus
resulting in the proximalized phenotype previously charac-
L. Huang et al. / Developmental Biology 278 (2005) 396–414 413terized by our laboratory (Prins et al., 2001a,b). It is also
possible that altered retinoid signaling contributes to
reduced Fgf10 expression as it does in the lung (Cardoso,
2001). This is notable since we have observed DLP-
specific expression of retinoid metabolizing enzymes and
binding proteins during prostatic development as well as
lobe-specific alterations in retinoid receptors, binding
proteins, and metabolizing enzymes following neonatal
estrogen exposure (Prins et al., 2002; Pu et al., 2003).
Thus, lobe-specific alterations in Fgf10 signaling could be
a result of estrogen-induced, lobe-specific alterations in
retinoid signaling. Recently, Tgfh1 was shown to down-
regulate prostatic Fgf10 expression (Tomlinson et al.,
2004), and this pathway may also be involved in the
estrogen-induced downregulation of Fgf10 since we have
previously observed an increase in latent and active Tgfh1
in stromal cells following neonatal estrogen exposure
(Chang et al., 1999). Perhaps multiple pathways contribute
to the alterations in expression of Fgf10 and other genes
following estrogen exposure that leads to the lobe-specific
and complex estrogenized phenotype. It is important to
note that since Fgf10 does not autoregulate FgfR2iiib, the
estrogen effect of decreased epithelial FgfR2 is most likely
not directly mediated through Fgf10 downregulation and
may involve these other pathways.
In conclusion, the present study provides evidence for
regulatory gene networks during prostate development that
allows for localized morphoregulatory factor expression and
controlled branching morphogenesis. Induction of positive
and negative regulators to modulate signaling activity is a
recurring theme in developing branched structures (Chuang
and McMahon, 2003), and the present findings demonstrate
that this process applies to the prostate gland as well. Our
findings also show that the lobe-specific responses to
neonatal estrogen exposures are a result of lobe-specific
alterations in the expression of several of these secreted
morphogens and their cognate receptors. Downregulation of
Fgf10 signaling appears to be a proximate cause of the
altered signaling cascade leading to branching deficits in the
dorsolateral prostate gland.Acknowledgments
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